Literature DB >> 20406099

CXCL12-3' G801A polymorphism is not a risk factor for breast cancer.

Łukasz Kruszyna1, Margarita Lianeri, Błazej Rubis, Hanna Knuła, Maria Rybczyńska, Sylwia Grodecka-Gazdecka, Paweł P Jagodziński.   

Abstract

The CXCL12-3' G801A transition (rs1801157) has been associated with the incidence of breast cancer. However, the contribution of CXCL12-3' G801A polymorphisms in breast cancer development and progression has been controversial. Therefore, we examined the incidence of CXCL12-3' G801A polymorphic variants in patients with breast cancer (n = 193) and controls (n = 199) in a Polish cohort. We observed a trend of slightly increased presence of CXCL12-3' AA and GA genotypes and CXCL12-3'A allele frequency in patients with breast cancer compared with healthy individuals. However, these differences between cases and controls were not statistically significant. Odds ratio (OR) for patients with breast cancer and the CXCL12-3' A/A genotype was 1.898 (95% confidence interval [CI] = 0.6242-5.770, p = 0.2866) and OR of the CXCL12-3' A/A and A/G genotypes was 1.229 (95% CI = 0.8082-1.868, p = 0.3395). OR for the CXCL12-3'A allele frequency was 1.249 (95% CI = 0.8716-1.789, p = 0.2352). Our investigation did not support the CXCL12-3'A gene variant as a risk factor for breast cancer incidence in a sample of the Polish population.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20406099     DOI: 10.1089/dna.2010.1030

Source DB:  PubMed          Journal:  DNA Cell Biol        ISSN: 1044-5498            Impact factor:   3.311


  9 in total

1.  CXCL12, CXCR4 and IFNγ genes expression: implications for proinflammatory microenvironment of breast cancer.

Authors:  Karen Brajão de Oliveira; Roberta Losi Guembarovski; Alda Maria Fiorina Losi Guembarovski; Ana Cristina da Silva do Amaral Herrera; Walter Jorge Sobrinho; Carolina Batista Ariza; Maria Angelica Ehara Watanabe
Journal:  Clin Exp Med       Date:  2012-06-15       Impact factor: 3.984

2.  Common sequence variants in chemokine-related genes and risk of breast cancer in post-menopausal women.

Authors:  Clara Bodelon; Katheleen E Malone; Lisa G Johnson; Mari Malkki; Effie W Petersdorf; Barbara McKnight; Margaret M Madeleine
Journal:  Int J Mol Epidemiol Genet       Date:  2013-11-28

3.  CXCL12 G801A polymorphism and breast cancer risk: a meta-analysis.

Authors:  Weisheng Shen; Xiangming Cao; Lei Xi; Lichun Deng
Journal:  Mol Biol Rep       Date:  2011-06-05       Impact factor: 2.316

4.  CXCL12 G801A polymorphism and cancer risk: An updated meta-analysis.

Authors:  Dan Meng; Yin-Xiang Wu; Vidhi Heerah; Shuang Peng; Meng-di Chu; Yong-Jian Xu; Wei-Ning Xiong; Shu-Yun Xu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2015-06-14

5.  CXCL12 chemokine and CXCR4 receptor: association with susceptibility and prognostic markers in triple negative breast cancer.

Authors:  Alda Losi Guembarovski; Roberta Losi Guembarovski; Bruna Karina Banin Hirata; Glauco Akelinghton Freire Vitiello; Karen Mayumi Suzuki; Mayara Tiemi Enokida; Maria Angelica Ehara Watanabe; Edna Maria Vissoci Reiche
Journal:  Mol Biol Rep       Date:  2018-06-20       Impact factor: 2.316

6.  The association between SDF-1 G801A polymorphism and non-small cell lung cancer risk in a Chinese Han population.

Authors:  Weiguo Xu; Rong Cui; Huapeng Yu
Journal:  Int J Clin Exp Med       Date:  2015-08-15

7.  The CXCL12 G801A polymorphism is associated with cancer risk: a meta-analysis.

Authors:  Ke Zhu; Benchun Jiang; Rong Hu; Ying Yang; Miao Miao; Yingchun Li; Zhuogang Liu
Journal:  PLoS One       Date:  2014-09-30       Impact factor: 3.240

8.  Associations of CXCL12 polymorphisms with clinicopathological features in breast cancer: a case-control study.

Authors:  Shuai Lin; Yi Zheng; Meng Wang; Linghui Zhou; Yuyao Zhu; Yujiao Deng; Ying Wu; Dai Zhang; Na Li; Huafeng Kang; Zhijun Dai
Journal:  Mol Biol Rep       Date:  2022-01-25       Impact factor: 2.316

9.  The SDF-1 rs1801157 Polymorphism is Associated with Cancer Risk: An Update Pooled Analysis and FPRP Test of 17,876 Participants.

Authors:  Xiang Tong; Yao Ma; Huajiang Deng; Xixi Wang; Sitong Liu; Zhipeng Yan; Shifeng Peng; Hong Fan
Journal:  Sci Rep       Date:  2016-06-06       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.